Fluorometholone

CHEMBL1200600 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
376.5 g/mol
LogP
2.0
Phase
4

This topical ophthalmic corticosteroid is used to treat inflammatory conditions of the eye, including allergic conjunctivitis and post-surgical inflammation. It has a lower risk of raising intraocular pressure compared to some other eye corticosteroids, making it preferred for certain inflammatory eye conditions.

Masse moléculaire

376,5000 g/mol

LogP

2,00

TPSA

74,60 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C

InChI

InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1

Molecular Formula

C22H29FO4

HBD / HBA

2 / 5

Liaisons Rotatives

1

Atomes Lourds

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This topical ophthalmic corticosteroid is used to treat inflammatory conditions of the eye, including allergic conjunctivitis and post-surgical inflammation. It has a lower risk of raising intraocular pressure compared to some other eye corticosteroids, making it preferred for certain inflammatory eye conditions.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Fluorometholone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200600. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9878. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.